

### The Lilly TB Drug Discovery Initiative's Board of Advisors

- **Dr. Barry Bloom** – Dean of the Faculty and Joan L. and Julius H. Jacobson Professor of Public Health at Harvard School of Public Health. Dr. Bloom is a leader in international health and a former consultant to the White House who continues to pursue an active interest in bench science as the principal investigator of a laboratory researching the immune response to TB.
- **Dr. Queta Bond** – Past President of the Burroughs-Wellcome Fund. Dr. Bond has served on the Board of Health Sciences Policy at the Institute of Medicine (IOM), as the Vice Chair of the Board of Scientific Counselors for the National Center for Infectious Diseases at the Centers for Disease Control and Prevention (CDC) and the chair of the Board of Regents of the National Library of Medicine.
- **Dr. Bruce Carter** – President and Chief Executive Officer, ZymoGenetics and a board member of the Global Alliance for TB Drug Development (TB Alliance). Dr. Carter has led Zymogenetics, a Seattle-based biotech, since 1998 and has transformed Zymogenetics from an early research enterprise to a solid product development company.
- **Dr. Gail Cassell** – Vice President, Lilly Scientific Affairs and Distinguished Research Scholar for Infectious Diseases. Dr. Cassell has been deeply involved in formulating science policy and legislation related to biomedical research and public health. She is a member of the IOM and serves on the IOM governing board. She recently served a three-year term on the Advisory Board of the Director of the CDC and as a member of the Secretary of Health and Human Services Advisory Council of Public Health Preparedness.
- **Dr. Paul Farmer** – Founder and Executive Director of Partners in Health, Presley Professor of Medical Anthropology at Harvard Medical School, and Associate Chief at the Division of Social Medicine and Health Inequalities at Brigham and Women's Hospital. Dr. Farmer's work draws primarily on active clinical practice and focuses on diseases that disproportionately afflict the poor. Dr. Farmer has pioneered novel, community-based treatment strategies for AIDS and TB (including multidrug-resistant tuberculosis).
- **Dr. Carole Heilman** – Director of the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Dr. Heilman manages the scientific direction, oversight, and management of all extramural research programs on infectious diseases within the NIH.
- **Dr. Barbara Laughon** – Senior Scientist for TB Drug Development Partnerships in the Office of the Director, DMID, NIAID, NIH. She is the primary NIH liaison with The Lilly TB Drug Discovery Initiative. She also serves as Chair of the Scientific Advisory Committee of the TB Alliance and was one of the original founding stakeholders of this public-private partnership. She is an active participant in the STOP-TB Partnership serving in working groups on New Drugs



The Lilly TB Drug Discovery Initiative

and TB/HIV co-infection. Dr. Laughon will serve as Executive Secretary of the Board of Advisors.

- **Dr. Regina Rabinovitch** – Director of Infectious Diseases for the Bill and Melinda Gates Foundation. Dr. Rabinovitch oversees the development and implementation of strategies for the prevention, treatment, and control of diseases of particular relevance to global health, including HIV/AIDS, TB, malaria, pneumonia, diarrhea, and neglected diseases.
- **Dr. Steve Reed** – Founder and Scientific Director of the Infectious Disease Research Institute (IDRI). Dr. Reed was also co-founder and Chief Scientific Officer of Corixa Corporation and founder of Dharma Therapeutics, a Seattle biotech developing transdermal delivery systems. Dr. Reed will serve as chair of the Board of Advisors.
- **Dr. George Whitesides** – Woodford L. and Ann A. Flowers University Professor at Harvard University. Dr. Whiteside has held advisory positions at the National Research Council, National Science Foundation and the Department of Defense. His present research interests include physical and organic chemistry, materials science, biophysics, complexity, surface science, microfluidics, self-assembly, micro- and nanotechnology, science for developing economies, origin of life, and cell-surface biochemistry.